Table 2. Factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma (HCC) assessed based on the best response on contrast-enhanced CT according to the modified response evaluation criteria in solid tumors (mRECIST) after 6 and 12 weeks of treatment.
| a) Evaluation in a total of 67 patients | ||||||||||
| Univariate analysis | Multivariate analysis | |||||||||
| Number of patients (%) | p- | Hazard ratio | 95%CI | p- | ||||||
| Total | CR | PR | SD | PD | values | values | ||||
| Age: years | < 70 | 22 | 1 (4.5) | 07 (31.8) | 12 (54.5) | 02 (09.1) | 0. 6675 | 1 | 0.319–3.420 | 0.9431 |
| ≥ 70 | 45 | 1 (2.2) | 13 (28.9) | 21 (46.7) | 10 (22.2) | 1.044 | ||||
| Etiology | Viral | 23 | 1 (4.3) | 08 (34.8) | 10 (43.5) | 04 (17.4) | 0. 4290 | 1 | 0.460–4.714 | 0.514 |
| non-viral | 44 | 1 (2.3) | 12 (27.3) | 23 (52.3) | 08 (18.2) | 1.473 | ||||
| mALBI | 1/ 2a | 42 | 1 (2.4) | 12 (28.6) | 21 (50.0) | 08 (19.0) | 0. 6707 | 1 | 0.191–2.089 | 0.4512 |
| grades | 2b | 25 | 1 (4.0) | 08 (32.0) | 12(48.0) | 04 (16.0) | 0.631 | |||
| BCLC | A/ B | 27 | 0 (0.0) | 09 (33.3) | 14 (51.9) | 04 (14.8) | 0. 9432 | 1 | 0.134–8.651 | 0.9456 |
| Stages | C | 40 | 2 (5.0) | 11 (27.5) | 19 (47.5) | 08 (20.0) | 1.075 | |||
| PVTT | Absent | 34 | 0 (0.0) | 11 (32.4) | 17 (50.0) | 06 (17.6) | 0. 9319 | 1 | 0.148–9.219 | 0.8833 |
| Present | 33 | 2 (6.1) | 09 (27.3) | 16 (48.5) | 06 (18.2) | 1.167 | ||||
| EH | Absent | 45 | 1 (2.2) | 15 (33.3) | 22 (48.9) | 07 (15.6) | 0. 4990 | 1 | 0.304–5.366 | 0.7383 |
| Metastasis | Present | 22 | 1 (4.5) | 05 (22.7) | 11 (50.0) | 05 (22.7) | 1.277 | |||
| AFP: ng/mL | < 200 | 32 | 0 (0.0) | 11 (34.4) | 18 (56.3) | 03 (09.4) | 0. 7976 | 1 | 0.325–4.389 | 0.789 |
| ≥ 200 | 35 | 2 (5.7) | 09 (25.7) | 15 (42.9) | 09 (25.7) | 1.194 | ||||
| N/L ratio | <2.7 | 32 | 0 (0.0) | 11 (34.4) | 13 (40.6) | 08 (25.0) | 0. 7976 | 1 | 0.320–3.068 | 0.9872 |
| ≥2.7 | 35 | 2 (5.7) | 09 (25.7) | 20 (57.1) | 04 (11.4) | 0.991 | ||||
| Previous TACE/TAI | Absent | 32 | 1 (3.1) | 11 (34.4) | 13 (40.6) | 7 (21.9) | 0.438 | 1 | 0.293–3.916 | 0.9176 |
| Present | 35 | 1 (2.9) | 9 (25.7) | 20 (57.1) | 5 (14.3) | 1.071 | ||||
| MTA | Naïve | 42 | 2 (4.8) | 15 (35.7) | 18 (42.9) | 07 (16.7) | 0. 0902 | 1 | 0.763–15.033 | 0.1087 |
| Experienced | 25 | 0 (0.0) | 05 (20.0) | 15 (60.0) | 05 (20.0) | 3.386 | ||||
| b) Evaluation in 65 patients consisting of 42 MTA-naïve patients and 23 patients after lenvatinib discontinuation due to PD or adverse events | ||||||||||
| Univariate analysis | Multivariate analysis | |||||||||
| Number of patients (%) | p- | Hazard ratio | 95%CI | p- | ||||||
| Total | CR | PR | SD | PD | values | values | ||||
| Age: years | < 70 | 22 | 1 (4.5) | 07 (31.8) | 12 (54.5) | 02 (09.1) | 0.6174 | 1 | 0.273–3.233 | 0.9201 |
| ≥ 70 | 43 | 1 (2.3) | 12 (27.9) | 20 (46.5) | 10 (23.3) | 0.939 | ||||
| Etiology | Viral | 22 | 1 (4.5) | 08 (36.4) | 09 (40.9) | 04 (18.2) | 0.2914 | 1 | 0.508–5.702 | 0.3883 |
| non-viral | 43 | 1 (2.3) | 11 (25.6) | 23 (53.5) | 08 (18.6) | 1.702 | ||||
| mALBI | 1/ 2a | 41 | 1 (2.4) | 11 (26.8) | 21 (51.2) | 08 (19.5) | 0.4943 | 1 | 0.142–1.760 | 0.2801 |
| grades | 2b | 24 | 1 (4.2) | 08 (33.3) | 11 (45.8) | 04 (16.7) | 0.499 | |||
| BCLC | A/ B | 27 | 0 (0.0) | 09 (33.3) | 14 (51.9) | 04 (14.8) | 0.8815 | 1 | 0.220–22.011 | 0.502 |
| Stages | C | 38 | 2 (5.3) | 10 (26.3) | 18 (47.4) | 08 (21.1) | 2.201 | |||
| PVTT | Absent | 33 | 0 (0.0) | 10 (30.3) | 17 (51.5) | 06 (18.2) | 0.7257 | 1 | 0.073–6.288 | 0.7305 |
| Present | 32 | 2 (6.3) | 09 (28.1) | 15 (46.9) | 06 (18.8) | 0.676 | ||||
| EH | Absent | 45 | 1 (2.2) | 15 (33.3) | 22 (48.9) | 07 (15.6) | 0.4034 | 1 | 0.274–5.645 | 0.7774 |
| Metastasis | Present | 20 | 1 (5.0) | 04 (20.0) | 10 (50.0) | 05 (25.0) | 1.244 | |||
| AFP: ng/mL | < 200 | 31 | 0 (0.0) | 10 (32.3) | 18 (58.1) | 03 (09.7) | 0.9935 | 1 | 0.316–4.485 | 0.7972 |
| ≥ 200 | 34 | 2 (5.9) | 09 (26.5) | 14 (41.2) | 09 (26.5) | 1.19 | ||||
| N/L ratio | <2.7 | 31 | 0 (0.0) | 10 (32.3) | 13 (41.9) | 08 (25.8) | 0.9935 | 1 | 0.239–2.577 | 0.6889 |
| ≥2.7 | 34 | 2 (5.9) | 09 (26.5) | 19 (55.9) | 04 (11.8) | 0.784 | ||||
| Previous TACE/TAI | Absent | 32 | 1 (3.1) | 11 (34.4) | 13 (40.6) | 7 (21.9) | 0.3796 | 1 | 0.296–4.321 | 0.8563 |
| Present | 33 | 1 (3.9) | 8 (24.2) | 19 (57.6) | 5 (15.2) | 1.132 | ||||
| Lenvatinib | Naïve | 42 | 2 (4.8) | 15 (35.7) | 18 (42.9) | 07 (16.7) | 0.0642 | 1 | 0.924–25.409 | 0.0619 |
| experienced | 23 | 0 (0.0) | 04 (17.4) | 14 (60.9) | 05 (21.7) | 4.846 | ||||